The IPO share price will be at a discount (because they are large blocks of shares), so I bet there will be phone calls to Biocurex by those investors that are on the fence on whether they're willing to purchase from the IPO because of the required holding periodand minimum sum required, or just trade on the open market. If you or someone really was wanting to accumulate shares (IMO there are plenty) they know to nibble or they could really make the share price elevate very rapidly.

I agree the potential for recaf is hard to put a true value on. That is why I will not let down on management culminating a reputation of excellence in their pursuit to launch recaf. The judgement on trust and belief in recaf will be heavily swayed on their perception of our company. All I know is that Dr Moro has corrected one of my sticking points in bringing on board a reputable spokeperson for Biocurex (Dr Berger). He fits the mold of a tried and tested, seasoned biotech executive. Shareholders agreed with my personal thoughts on the day of the announcement when we added 2 new well- connected executives, and the share price advanced immensely on that news alone. My goal is to make it clear that my investment is riding on how they plan on educating and reaching the largest audience possible. Not just doctors, but patients and dog lovers. You have to cultivate a reputation first and give your potential customers a reason to want your product. If you plan on having dog recaf done inhouse, I would expect top notch customer relations that are trained and well educated, because there will be plenty of questions. You might want to survey doctors and potential customers now, so you are prepared for what lies ahead. I also hope Biocurex is training the technicians in anticipation of the launch. Poor customer service could easily kill the goose that lays the golden egg. Don't go into this with a "trial by fire" attitude, because you will never get a second chance if you don't get it right the first time.